{"schema_version":"secwatch.filing_event.v1","accession":"0001662774-24-000004","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.020545+00:00","generated_at":"2026-05-31T09:44:38.895695+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Quince Therapeutics Q2 net loss $27.7M; Phase 3 NEAT on track for Q4 2025 topline","bullets":["Cash $59.4M at June 30; expects runway into 2026 through Phase 3 NEAT topline results.","Net loss $27.7M ($0.64/share) includes $17.1M goodwill impairment; R&D $4.2M, G&A $4.7M.","Phase 3 NEAT enrolled 7 patients; topline results expected Q4 2025; NDA/MAA in 2026 if positive.","FDA Fast Track for EryDex in A-T; diagnosed U.S. patients estimated at ~4,600 (up from ~3,400).","Planning DMD proof-of-concept study in 2025; evaluating partnerships for ex-U.S. rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001662774-24-000004","json":"https://secwatch.observer/filing/0001662774-24-000004.json","markdown":"https://secwatch.observer/filing/0001662774-24-000004.md","text":"https://secwatch.observer/filing/0001662774-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000166277424000004/0001662774-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000166277424000004/qncx-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:44:38.895695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}